US Patent

US11065250 — Solid dosage forms of palbociclib

Formulation · Assigned to Pfizer Inc · Expires 2036-08-19 · 10y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects solid dosage forms of the drug palbociclib that contain a water-soluble acid.

USPTO Abstract

The present invention relates to solid dosage forms of palbociclib comprising a water-soluble acid. The dosage forms described herein have desirable pharmacokinetic characteristics.

Drugs covered by this patent

Palbociclib (palbociclib) · Pfizer Inc.

Patent Metadata

Patent number: US11065250
Jurisdiction: US
Classification: Formulation
Expires: 2036-08-19
Drug substance claim: No
Drug product claim: Yes
Assignee: Pfizer Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.